Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) was the target of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 76,183 shares, a decline of 23.2% from the February 26th total of 99,192 shares. Based on an average trading volume of 17,232 shares, the short-interest ratio is presently 4.4 days. Currently, 0.1% of the company’s shares are short sold.

Innate Pharma Price Performance

IPHA traded down $0.04 during trading hours on Monday, reaching $1.26. 17,170 shares of the company’s stock traded hands, compared to its average volume of 22,457. The firm has a 50-day moving average price of $1.61 and a 200 day moving average price of $1.80. Innate Pharma has a 52-week low of $1.17 and a 52-week high of $2.63.

Institutional Trading of Innate Pharma

A number of large investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in Innate Pharma in the 4th quarter worth about $36,000. OLD Mission Capital LLC bought a new stake in Innate Pharma during the 4th quarter valued at about $50,000. Finally, Jane Street Group LLC purchased a new stake in Innate Pharma in the 4th quarter valued at about $162,000. 0.16% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IPHA shares. BTIG Research assumed coverage on shares of Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.